Financial Review: Biostage (OTCMKTS:BSTG) versus Nemaura Medical (OTCMKTS:NMRD)

Biostage (OTCMKTS:BSTG) and Nemaura Medical (OTCMKTS:NMRD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Volatility & Risk

Biostage has a beta of -1.02, meaning that its stock price is 202% less volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Biostage and Nemaura Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biostage	0	0	1	0	3.00
Nemaura Medical	0	0	0	0	0.00

Given Nemaura Medical’s higher probable upside, analysts plainly believe Nemaura Medical is more favorable than Biostage.

Earnings & Valuation

This table compares Biostage and Nemaura Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biostage	N/A	N/A	-$6.07 million	($0.58)	-7.67
Nemaura Medical	$80,000.00	0.00	-$14.14 million	($0.50)	N/A

Biostage has higher earnings, but lower revenue than Nemaura Medical. Biostage is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

4.4% of Nemaura Medical shares are held by institutional investors. 15.3% of Biostage shares are held by company insiders. Comparatively, 40.4% of Nemaura Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Biostage and Nemaura Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biostage	N/A	N/A	-174.43%
Nemaura Medical	N/A	N/A	N/A

Summary

Nemaura Medical beats Biostage on 7 of the 10 factors compared between the two stocks.

About Biostage

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.